Report Code : CVMI2501154 | Published Date : March 3, 2025

Market Overview:

The global melanoma treatment market encompasses therapies targeting malignant melanoma, the most aggressive form of skin cancer. Driven by rising UV exposure, genetic predisposition, and improved diagnostic technologies, the market is shifting toward immunotherapies (PD-1/CTLA-4 inhibitors), targeted therapies (BRAF/MEK inhibitors), and AI-driven early detection tools. North America and Europe dominate due to high awareness and reimbursement policies, while Asia-Pacific shows rapid growth with increasing healthcare investments.

 

Market Size and Forecast

Year

Market Value (USD Billion)

Notes

2023

5.2

Immunotherapies account for 55% revenue.

2028

8.6

CAGR 10.5% (2023–2028): BRAF/MEK combos gain traction.

2035

12.4

CAGR 9.8% (2028–2035): mRNA vaccines and AI diagnostics scale.

By 2035, over 500,000 patients annually will receive advanced therapies, with immunotherapy adoption expected to double in emerging markets.

 

Market Drivers

  • Immunotherapy breakthroughs: PD-1 inhibitors (Keytruda, Opdivo) improve five-year survival to 40% (vs. 15% pre-2015).
  • Precision medicine: Biomarker testing (BRAF, NRAS) informs 70% of treatment decisions in the U.S. and EU.
  • AI diagnostics: Tools like DermEngine decrease late-stage diagnoses by 25%.
  • Government initiatives: NIH and EU Horizon fund over 120 clinical trials for metastatic melanoma.

 

Market Challenges

  • High costs: Immunotherapy averages USD 150,000 per year, limiting access in LMICs.
  • Side effects: 30% of patients stop using CTLA-4 inhibitors because of toxicity.
  • Regulatory delays: The Asia-Pacific region lags in approvals (e.g., China’s NMPA takes over 3 years compared to the FDA’s 12 months). Competitive Landscape

Company

2023 Share

Core Strengths

Recent Moves

Merck & Co.

35%

Keytruda (PD-1 inhibitor)

Expanded adjuvant use to Stage IIB (2024).

Bristol-Myers Squibb

28%

Opdivo + Yervoy combo

Phase III trials for ocular melanoma (2025).

Novartis

15%

Tafinlar + Mekinist (BRAF/MEK)

Launched liquid biopsy companion test (2024).

Startups (e.g., NeraCare)

22%

AI staging tools

Raised USD 300M for hyperspectral imaging (2025).

 

Market Segmentation

Segment

2023 Share

CAGR (2023–2035)

By Therapy

    

Immunotherapy

55%

11.2%

Targeted Therapy

30%

9.5%

By Stage

    

Stage III–IV

XX%

10.8%

Stage 0–II (adjuvant)

XX%

13.1%

 

Regional Analysis

  • North America (48%): The U.S. has 90% insurance coverage for immunotherapies.
  • Europe (XX%): Germany’s universal biomarker testing fuels 15% annual growth.
  • Asia-Pacific (XX%): Japan accelerates novel therapies (e.g., Delcath’s CHEMOSAT).

 

Technology & Innovation

  • mRNA vaccines: Moderna/BioNTech’s personalized melanoma vaccine (Phase III, 2025).
  • Liquid biopsies: Guardant360 CDx gains FDA approval for resistance monitoring (2024).
  • AI-pathology: Paige.AI’s algorithm detects micro-metastases with 95% accuracy.

 

Regulatory Environment

  • FDA: Accelerated approvals for TIL therapies (e.g., Iovance’s Lifileucel).
  • EMA mandates companion diagnostics for BRAF inhibitors.
  • China's NMPA prioritizes domestic PD-1 inhibitors, such as Toripalimab.

 

Strategic Outlook

  • Hospitals: Must invest in biomarker testing infrastructure.
  • Pharma: Focus on combo therapies to overcome resistance.
  • Payers: Expand reimbursement for early-stage adjuvant treatments.




Reasons To Buy

Image



Scope

Image

Key Players

  • Hoffmann‑La Roche Ltd
  • Bristol‑Myers Squibb
  • Novartis AG
  • Genentech Inc.
  • AstraZeneca plc
  • Sanofi S.A.
  • Amgen Inc.
  • Takeda Pharmaceutical Company
  • Merck & Co Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • Moderna Inc.
  • Iovance Biotherapeutics Inc.

Melanoma Treatment Market Report


  1. 1. Melanoma Treatment Market Research Report
    1. 1.1 Study Objectives
    2. 1.2 Melanoma Treatment Market - Overview
    3. 1.3 Reason to Read This Report
    4. 1.4 Methodology and Forecast Analysis
  2. 2. Melanoma Treatment Market Research Report - Preface
    1. 2.1 Melanoma Treatment Market Research Report – Detailed Scope and Definitions
      1. 2.1.1 By Therapy
      2. 2.1.2 By Stage
      3. 2.1.3 By Region
  3. 3. Melanoma Treatment Market Dynamics
    1. 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
    2. 3.2. Restraints – By Therapy, By Stage, By Country
    3. 3.3. Opportunities – By Therapy, By Stage, By Country
    4. 3.4. Trends – By Therapy, By Stage, By Country
    5. 3.5. PEST Analysis
    6. 3.6. Porters Five Rule Analysis
    7. 3.7. Company’s Share Analysis (CSA) by Region or By Country
    8. 3.8. Melanoma Treatment Market Research Report – DROTs Impact Analysis
    1. 4. Melanoma Treatment Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
    2. 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
    4. 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
    5. 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 5. Melanoma Treatment Market, By Therapy, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 5.1 Immunotherapy
    2. 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 5.2 Targeted Therapy
    7. 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. Melanoma Treatment Market, By Stage, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 6.1 Stage III–IV
    2. 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    3. 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    4. 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    5. 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
    6. 6.2 Stage 0–II (adjuvant)
    7. 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
    8. 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
    9. 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
    10. 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
  1. 7. Melanoma Treatment Market Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
    1. 7.1 North America
      1. 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.2 Europe
      1. 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.3 Asia-Pacific
      1. 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.4 Latin America
      1. 7.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.5 Middle East and Africa
      1. 7.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
      2. 7.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
      3. 7.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
      4. 7.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
      7.6 Melanoma Treatment Market - Opportunity Analysis Index, By Therapy, By Stage, and Region, 2024 - 2031
  1. 8. North America Melanoma Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 8.1 By Therapy Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.1.1 Immunotherapy
      2. 8.1.2 Targeted Therapy
      8.2 By Stage Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.2.1 Stage III–IV
      2. 8.2.2 Stage 0–II (adjuvant)
      8.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 8.3.1 United States
      2. 8.3.2 Canada
    2. 8.4 North America Melanoma Treatment Market – Opportunity Analysis Index, By Therapy, By Stage, and Country, 2024 - 2031
    3. 8.5 Regional Trends Analysis
    4. 8.6 North America Melanoma Treatment Market Research Report - Company Profiles
      1. 8.6.1 Company 1 (United States)
      2. 8.6.2 Company 2 (Canada)
      3. 8.6.3 Company 3 (Canada)
    9. Europe Melanoma Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 9.1 By Therapy Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.1.1 Immunotherapy
      2. 9.1.2 Targeted Therapy
      9.2 By Stage Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.2.1 Stage III–IV
      2. 9.2.2 Stage 0–II (adjuvant)
      9.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 9.3.1 Germany
      2. 9.3.2 United Kingdom
      3. 9.3.3 France
      4. 9.3.4 Spain
      5. 9.3.5 Italy
      6. 9.3.6 Russia
    2. 9.4 Europe Melanoma Treatment Market – Opportunity Analysis Index, By Therapy, By Stage, and Country, 2024 - 2031
    3. 9.5 Regional Trends Analysis
    4. 9.6 Europe Melanoma Treatment Market Research Report - Company Profiles
      1. 9.6.1 Company 1 (Germany)
      2. 9.6.2 Company 2 (United Kingdom)
      3. 9.6.3 Company 3 (United Kingdom)
    10. Asia-Pacific Melanoma Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 10.1 By Therapy Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.1.1 Immunotherapy
      2. 10.1.2 Targeted Therapy
      10.2 By Stage Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.2.1 Stage III–IV
      2. 10.2.2 Stage 0–II (adjuvant)
      10.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 10.3.1 China
      2. 10.3.2 Japan
      3. 10.3.3 India
      4. 10.3.4 South Korea
      5. 10.3.5 Australia & New Zealand
      6. 10.3.6 ASEAN
    2. 10.4 Asia-Pacific Melanoma Treatment Market – Opportunity Analysis Index, By Therapy, By Stage, and Country, 2024 - 2031
    3. 10.5 Regional Trends Analysis
    4. 10.6 Asia-Pacific Melanoma Treatment Market Research Report - Company Profiles
      1. 10.6.1 Company 1 (China)
      2. 10.6.2 Company 2 (Japan)
      3. 10.6.3 Company 3 (Japan)
    11. Latin America Melanoma Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 11.1 By Therapy Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.1.1 Immunotherapy
      2. 11.1.2 Targeted Therapy
      11.2 By Stage Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.2.1 Stage III–IV
      2. 11.2.2 Stage 0–II (adjuvant)
      11.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 11.3.1 Brazil
      2. 11.3.2 Mexico
      3. 11.3.3 Argentina
      4. 11.3.4 Peru
      5. 11.3.5 Colombia
      6. 11.3.6 Rest of Latin America
    2. 11.4 Latin America Melanoma Treatment Market – Opportunity Analysis Index, By Therapy, By Stage, and Country, 2024 - 2031
    3. 11.5 Regional Trends Analysis
    4. 11.6 Latin America Melanoma Treatment Market Research Report - Company Profiles
      1. 11.6.1 Company 1 (Brazil)
      2. 11.6.2 Company 2 (Mexico)
      3. 11.6.3 Company 3 (Mexico)
    12. Middle East and Africa Melanoma Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
    1. 12.1 By Therapy Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.1.1 Immunotherapy
      2. 12.1.2 Targeted Therapy
      12.2 By Stage Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.2.1 Stage III–IV
      2. 12.2.2 Stage 0–II (adjuvant)
      12.3 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
      1. 12.3.1 Saudi Arabia
      2. 12.3.2 UAE
      3. 12.3.3 South Africa
      4. 12.3.4 Egypt
      5. 12.3.5 Israel
      6. 12.3.6 Rest of Middle East and Africa
    2. 12.4 Middle East and Africa Melanoma Treatment Market – Opportunity Analysis Index, By Therapy, By Stage, and Country, 2024 - 2031
    3. 12.5 Regional Trends Analysis
    4. 12.6 Middle East and Africa Melanoma Treatment Market Research Report - Company Profiles
      1. 12.6.1 Company 1 (Saudi Arabia)
      2. 12.6.2 Company 2 (UAE)
      3. 12.6.3 Company 3 (UAE)
    13. Competition Landscape
    1. 13.1 Strategic Dashboard of Top Market Players
    2. 13.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
      1. 13.2.1 Bristol‑Myers Squibb
      2. 13.2.2 Merck & Co.
      3. 13.2.3 Novartis AG
      4. 13.2.4 F. Hoffmann‑La Roche Ltd.
      5. 13.2.5 AstraZeneca
      6. 13.2.6 Amgen Inc.
      7. 13.2.7 Pfizer Inc.
      8. 13.2.8 Sanofi S.A.
      9. 13.2.9 Takeda Pharmaceutical Company
      10. 13.2.10 Johnson & Johnson
      11. 13.2.11 Bayer AG
      12. 13.2.12 GlaxoSmithKline plc
      13. 13.2.13 Iovance Biotherapeutics Inc.
      14. 13.2.14 Polynoma LLC
      15. 13.2.15 Moderna
  1. 14. Data Collection Method and Research Approach
  2. 15. Principal Presumptions and Acronyms